Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Teva
Queensland Health
Covington
Cipla
McKesson
Argus Health
AstraZeneca
US Army

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,278,105

« Back to Dashboard

Which drugs does patent 9,278,105 protect, and when does it expire?

Patent 9,278,105 protects MINOCIN and is included in one NDA.

This patent has twenty-four patent family members in twenty-one countries.
Summary for Patent: 9,278,105
Title:Tetracycline compositions
Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
Inventor(s): Griffith; David C. (San Marcose, CA), Boyer; Serge (San Diego, CA), Dudley; Michael N. (San Diego, CA), Hecker; Scott (Del Mar, CA)
Assignee: Rempex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/654,018
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,278,105

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Rempex Pharms MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF TREATING BACTERIAL INFECTIONS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,278,105

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,084,802 Tetracycline compositions ➤ Try a Free Trial
9,744,179 Tetracycline compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,278,105

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 347919 ➤ Try a Free Trial
Mexico 2012012993 ➤ Try a Free Trial
South Korea 101799304 ➤ Try a Free Trial
South Korea 20130080797 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
UBS
Cerilliant
Chubb
Boehringer Ingelheim
Colorcon
QuintilesIMS
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.